Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Arthur J Gallagher & Co / Equity Bottom-Up

<ul><li>Arthur J.</li><li>Gallagher & Co. reported a quarter that combined solid underlying growth with a material step-up from acquisitions, while also exposing some timing and mix items that can create volatility in quarterly comparisons.</li><li>Total revenue increased 20% driven by both organic activity and merger integration, with organic growth of 4.8%.</li></ul>

Arthur J.Gallagher & Co. reported a quarter that combined solid underlying growth with a material step-up from acquisitions, while also exposing some timing and mix items that can create volatility in quarterly comparisons.Total revenue increased 20% driven by both organic activity and merger integration, with organic growth of 4.8%.

Arthur J. Gallagher & Co.: Inside the AssuredPartners Synergy Playbook & the $160M-$280M Margin Upside!

<ul><li>Albertsons Companies' second-quarter earnings for 2025 reflect a nuanced performance with both positive strides and areas of cautious optimism.</li><li>The company reported adjusted identical sales growth of 2.2%, with notable contributions from a 23% increase in digital sales and robust growth in its pharmacy segment, which includes significant share gains from competitor store closures.</li><li>Adjusted EBITDA stood at $848 million, while adjusted earnings per share came in at $0.44, consistent with company expectations.</li></ul>

Albertsons Companies' second-quarter earnings for 2025 reflect a nuanced performance with both positive strides and areas of cautious optimism.The company reported adjusted identical sales growth of 2.2%, with notable contributions from a 23% increase in digital sales and robust growth in its pharmacy segment, which includes significant share gains from competitor store closures.Adjusted EBITDA stood at $848 million, while adjusted earnings per share came in at $0.44, consistent with company expectations.

Arthur J Gallagher & Co - Albertsons Companies: An Insight Into Its Technology

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/steadfast-group-ltd" target="_blank" data-smartkarma-citation="entities:8181:1" rel="noopener">Steadfast (SDF AU)</a> has entered a SID with Amwins, Dragoneer and KKR at A$6.00 per share, a 51.9% premium to the undisturbed price of A$3.95.</li>
<li>Since the disclosure of the non-binding proposal, the peers have materially re-rated, and the offer remains light compared to precedent transactions. </li>
<li>However, the scheme vote should pass, as the offer is reasonable relative to peer multiples and AusSuper, the largest shareholder, has not publicly opposed it.  </li>
</ul>



Steadfast (SDF AU) has entered a SID with Amwins, Dragoneer and KKR at A$6.00 per share, a 51.9% premium to the undisturbed price of A$3.95.
Since the disclosure of the non-binding proposal, the peers have materially re-rated, and the offer remains light compared to precedent transactions. 
However, the scheme vote should pass, as the offer is reasonable relative to peer multiples and AusSuper, the largest shareholder, has not publicly opposed it.  


Steadfast (SDF AU): Consortium’s Binding Proposal at A$6.00 as Peers Have Materially Re-Rated

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>The S&amp;P 500 is 1% above the 4300-4325 area which we anticipated would cap upside for 2023.</li>
<li>Our view since our 5/30/23 ETF Pathfinder is that we cannot be bearish if the SPX is above 4050, and we subsequently moved that line-in-the-sand up to 4165-4200 on 6/6/23.</li>
<li>We are moving that threshold up to 4300, which is short-term support to watch; a break below it could bring selling pressure.</li>
</ul>


The S&amp;P 500 is 1% above the 4300-4325 area which we anticipated would cap upside for 2023.
Our view since our 5/30/23 ETF Pathfinder is that we cannot be bearish if the SPX is above 4050, and we subsequently moved that line-in-the-sand up to 4165-4200 on 6/6/23.
We are moving that threshold up to 4300, which is short-term support to watch; a break below it could bring selling pressure.


Consolidation Likely, But Little Reason to Be Bearish; Buys Within Biotech, Latin American Banks

VanEck Gold Miners ETF/USA / Technical Analysis

<ul>
<li>Since late-January/early-February we've recommended shifting to defensives considering our belief that 4165-4200 will cap upside on the $SPX in 2023, while also conceding that a reach to 4300-4325 is possible.</li>
<li>Considering limited upside in both scenarios, we continue to recommend shifting to defensives and believe that now is the time to be tactically overweight defensives</li>
<li>Defensive Sectors including Health Care (XLV), Utilities (XLU), and Staples (XLP) are hitting 2+ month RS highs, and are staging bullish price and RS reversals, as are gold miners (GDX). </li>
</ul>


Since late-January/early-February we've recommended shifting to defensives considering our belief that 4165-4200 will cap upside on the $SPX in 2023, while also conceding that a reach to 4300-4325 is possible.
Considering limited upside in both scenarios, we continue to recommend shifting to defensives and believe that now is the time to be tactically overweight defensives
Defensive Sectors including Health Care (XLV), Utilities (XLU), and Staples (XLP) are hitting 2+ month RS highs, and are staging bullish price and RS reversals, as are gold miners (GDX). 


Defensive Areas Starting to Lead; 10-Yr Treasury Yield Testing Support at 3.35-3.4%

United States

Arthur J. Gallagher & Co. and its subsidiaries provide insurance brokerage, risk management, employee benefit, and other related services to clients in the United States and abroad. The Company's principal activity is the negotiation and placement of insurance for its clients. Gallagher also specializes in furnishing risk management services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Arthur J Gallagher & Co (AJG US)

Arthur J. Gallagher & Co.: Inside the AssuredPartners Synergy Playbook & the $160M-$280M Margin Upside!

Arthur J. Gallagher & Co. reported a quarter that combined solid underlying growth with a material step-up from acquisitions, while also...

Baptista Research

Arthur J Gallagher & Co - Albertsons Companies: An Insight Into Its Technology

Albertsons Companies' second-quarter earnings for 2025 reflect a nuanced performance with both positive strides and areas of cautious...

Baptista Research

Steadfast (SDF AU): Consortium’s Binding Proposal at A$6.00 as Peers Have Materially Re-Rated

Despite the material re-rating of peers, the scheme vote should pass. At the last close and for an end-of-December payment, the gross/annualised...

Arun George

Consolidation Likely, But Little Reason to Be Bearish; Buys Within Biotech, Latin American Banks

$SPX is 1% above 4300-4325 which we anticipated would cap upside for 2023. Our view since May 30 (ETF Pathfinder) is we cannot be bearish if SPX is...

Vermilion Research

Defensive Areas Starting to Lead; 10-Yr Treasury Yield Testing Support at 3.35-3.4%

Defensive Sectors including Health Care $XLV, Utilities $RYU $XLU, and Staples $XLP are hitting 2+ month RS highs, and are staging bullish price...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)